These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38982437)

  • 1. Costs and healthcare use of patients with chronic kidney disease in the Northern Territory, Australia.
    Chen W; Howard K; Gorham G; Abeyaratne A; Zhao Y; Adegboye O; Kangaharan N; Talukder MRR; Taylor S; Cass A;
    BMC Health Serv Res; 2024 Jul; 24(1):791. PubMed ID: 38982437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Annual health care resource utilization and cost among type 2 diabetes patients with newly recognized chronic kidney disease within a large U.S. administrative claims database.
    Folkerts K; Petruski-Ivleva N; Kelly A; Fried L; Blankenburg M; Gay A; Kovesdy CP
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1506-1516. PubMed ID: 33251992
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost to government and society of chronic kidney disease stage 1-5: a national cohort study.
    Wyld ML; Lee CM; Zhuo X; White S; Shaw JE; Morton RL; Colagiuri S; Chadban SJ
    Intern Med J; 2015 Jul; 45(7):741-7. PubMed ID: 25944415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
    Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
    BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incident haemodialysis and outcomes in the Top End of Australia.
    Hughes JT; Majoni SW; Barzi F; Harris TM; Signal S; Lowah G; Kapojos J; Abeyaratne A; Sundaram M; Goldrick P; Jones SL; McFarlane R; Campbell LT; Stephens D; Cass A
    Aust Health Rev; 2020 Apr; 44(2):234-240. PubMed ID: 30995950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of algorithms to identify patients with chronic kidney disease and related chronic diseases across the Northern Territory, Australia.
    Chen W; Abeyaratne A; Gorham G; George P; Karepalli V; Tran D; Brock C; Cass A
    BMC Nephrol; 2022 Sep; 23(1):320. PubMed ID: 36151531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure.
    Nichols GA; Ustyugova A; Déruaz-Luyet A; O'Keeffe-Rosetti M; Brodovicz KG
    J Am Soc Nephrol; 2020 Jul; 31(7):1594-1601. PubMed ID: 32487562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inside ANEMIA of CKD: Projecting the Future Burden of Anemia of Chronic Kidney Disease and Benefits of Proactive Management: A Microsimulation Model of the Chinese Population.
    Retat L; Xiao D; Webber L; Martin A; Card-Gowers J; Yao J; Zhang Y; Zhang C; Garcia Sanchez JJ; Cabrera C; Grandy S; Rao N; Wu Y; Li Z; Xuan J
    Adv Ther; 2024 Oct; 41(10):3905-3921. PubMed ID: 39162981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
    Kent S; Schlackow I; Lozano-Kühne J; Reith C; Emberson J; Haynes R; Gray A; Cass A; Baigent C; Landray MJ; Herrington W; Mihaylova B;
    BMC Nephrol; 2015 Apr; 16():65. PubMed ID: 25924679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme.
    Jha V; Al-Ghamdi SMG; Li G; Wu MS; Stafylas P; Retat L; Card-Gowers J; Barone S; Cabrera C; Garcia Sanchez JJ
    Adv Ther; 2023 Oct; 40(10):4405-4420. PubMed ID: 37493856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
    Lage MJ; Boye KS; Bae JP; Wu J; Mody R; Botros FT
    J Med Econ; 2019 May; 22(5):447-454. PubMed ID: 30736708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs.
    Vekeman F; Magestro M; Karner P; Duh MS; Nichols T; van Waalwijk van Doorn-Khosrovani SB; Zonnenberg BA
    J Med Econ; 2015; 18(12):1060-70. PubMed ID: 26201433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do remote dialysis services really cost more? An economic analysis of hospital and dialysis modality costs associated with dialysis services in urban, rural and remote settings.
    Gorham G; Howard K; Cunningham J; Barzi F; Lawton P; Cass A
    BMC Health Serv Res; 2021 Jun; 21(1):582. PubMed ID: 34140001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
    Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
    J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives.
    Aoun M; Helou E; Sleilaty G; Zeenny RM; Chelala D
    BMC Health Serv Res; 2022 May; 22(1):586. PubMed ID: 35501814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.
    Chiroli S; Mattin C; Belozeroff V; Perrault L; Mitchell D; Gioni I
    BMC Nephrol; 2012 Oct; 13():140. PubMed ID: 23106934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-cause costs increase exponentially with increased chronic kidney disease stage.
    Golestaneh L; Alvarez PJ; Reaven NL; Funk SE; McGaughey KJ; Romero A; Brenner MS; Onuigbo M
    Am J Manag Care; 2017 Jun; 23(10 Suppl):S163-S172. PubMed ID: 28978205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data.
    van Oosten MJM; Logtenberg SJJ; Leegte MJH; Bilo HJG; Mohnen SM; Hakkaart-van Roijen L; Hemmelder MH; de Wit GA; Jager KJ; Stel VS
    Nephrol Dial Transplant; 2020 Dec; 35(12):2138-2146. PubMed ID: 31598728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.